title: An update on the treatment and management of stroke.
abstract: There have been huge advancements in the prophylaxis and treatment of stroke. The majority of patients who have a stroke are asymptomatic prior to the event. This makes it extremely important to identify high-risk patients and administer prophylaxis where appropriate. However, risk factors, prophylaxis and treatment strategies are less clear in dialysis patients due to the lack of studies. Patients with chronic kidney disease have a higher risk of experiencing a stroke and dying from it. More studies need to be done in this area. For now, modifiable risk factors such as blood pressure and nutrition, should be promoted and prophylaxis and treatment administered with extra vigilance due to these patients' increased bleeding risk.
authors.affiliation: London Health Sciences Centre, Ontario. Seadna.Ledger@lhsc.on.ca
authors.forename: Séadna
authors.initials: S
authors.lastname: Ledger
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D002170:Canada / Q000453:epidemiology; D016894:Endarterectomy, Carotid; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D011322:Primary Prevention; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D000074606:Smoking Prevention; D020521:Stroke / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator